everolimus sandoz tablett
sandoz pharmaceuticals d.d. - everoliimus - tablett - 5mg 30tk; 5mg 90tk; 5mg 10tk
everolimus sandoz tablett
sandoz pharmaceuticals d.d. - everoliimus - tablett - 2,5mg 90tk; 2,5mg 10tk; 2,5mg 30tk
everolimus norameda tablett
norameda uab - everoliimus - tablett - 5mg 90tk; 5mg 30tk; 5mg 10tk
everolimus teva tablett
teva b.v. - everoliimus - tablett - 10mg 10tk; 10mg 60tk; 10mg 90tk; 10mg 30tk
everolimus sandoz tablett
sandoz pharmaceuticals d.d. - everoliimus - tablett - 10mg 10tk; 10mg 90tk
everolimus norameda tablett
norameda uab - everoliimus - tablett - 10mg 30tk; 10mg 90tk; 10mg 10tk
everolimus norameda tablett
norameda uab - everoliimus - tablett - 2,5mg 30tk; 2,5mg 90tk
temsirolimus accord infusioonilahuse kontsentraat ja lahusti
accord healthcare b.v. - temsiroliimus - infusioonilahuse kontsentraat ja lahusti - 30mg 1ml 1.2ml 1tk
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , kolmekordne kombineeritud ravi) lisandina toitumise ja treeningu patsientidel, ebapiisavalt kontrollitud nende maksimaalne talutav annus metformiin ja sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.